CoDiagnostics CODX not too long ago introduced that the Australian Patent Workplace has granted a patent masking its new Co-Dx PCR platform, marking the primary patent issued for this point-of-care know-how.
From an investor perspective, the patent strengthens CODX’s long-term commercialization technique by securing IP in a area that would turn out to be an necessary future market. Whereas the platform continues to be beneath regulatory assessment and never but accessible on the market, the milestone helps administration’s push to develop international safety for its PCR know-how because it targets decentralized and point-of-care testing alternatives.
Doubtless Development of CODX Inventory Following the Information
Following the announcement, CODX shares misplaced 21.1% at yesterday’s market closing. Shares of the corporate have misplaced 35.5% within the final six-month interval in opposition to the trade’s 6.2% progress. The S&P 500 has gained 14.1% in the identical timeframe.
In the long term, the Australian patent strengthens CODX by securing defensible mental property round its point-of-care PCR platform, decreasing aggressive threat and defending future commercialization potential. The added IP protection enhances CODX’s leverage with potential companions and distributors whereas preserving pricing energy and recurring income alternatives tied to devices and consumables, supporting a extra sturdy platform-driven progress story as soon as regulatory approvals are in place.
CODX at the moment has a market capitalization of $13.9 million.
Picture Supply: Zacks Funding Analysis
Extra on the Information
CODX introduced that the Australian Patent Workplace has granted Patent No. AU2022270084A1, marking the primary issued patent for its new Co-Dx PCR platform. Filed in Could 2022 and granted in June 2025, the patent supplies broad safety masking the system and strategies used for nucleic acid detection and evaluation. The claims particularly embody the design and operation of the Co-Dx PCR Professional instrument and its proprietary take a look at cups, supporting high-quality PCR testing in point-of-care and decentralized settings relatively than conventional labs.
From a strategic standpoint, securing patent safety in Australia strengthens the corporate’s international IP portfolio because it evaluates future commercialization and partnership alternatives within the area. The transfer is well timed given Australia’s current report flu season, which highlights rising demand for speedy and accessible molecular diagnostics.
The patent additionally helps the long-term business potential of the Co-Dx PCR Flu A/B, COVID, and RSV multiplex take a look at, at the moment in scientific efficiency testing. Whereas the platform stays beneath regulatory assessment and isn’t but accessible on the market, the patent positions CODX to guard its know-how and future income alternatives forward of broader market entry.
Favorable Business Prospects for CODX
Per a report by Grand View Analysis, the worldwide molecular diagnostics market dimension was estimated at $18.85 billion in 2025 and is projected to achieve $25.59 billion by 2033, increasing at a CAGR of 4.06% from 2026 to 2033.
Key drivers of this progress embody ongoing technological developments, a steadily ageing inhabitants, and rising demand for exact, environment friendly genetic testing options.
Different Current Developments for CODX
Not too long ago, CODX introduced that an in-silico evaluation of the Co-Primers utilized in its Logix Sensible ABC take a look at demonstrated excessive homology throughout roughly 3,900 influenza sequences, supporting robust and constant detection of influenza A, influenza B and COVID-19. Notably, the outcomes confirmed comparable reactivity in opposition to the influenza A H3N2 subclade Ok, reinforcing confidence within the take a look at’s robustness as flu strains evolve and highlighting the sturdiness of CODX’s primer design in sustaining diagnostic accuracy over time.
CODX’s Zacks Rank & Different Key Picks
Presently, CODX carries a Zacks Rank #2 (Purchase).
Another top-ranked shares from the broader medical area are Intuitive Surgical ISRG, Medpace Holdings MEDP and Boston Scientific BSX.
Intuitive Surgical, sporting a Zacks Rank #1 (Robust Purchase) at current, posted a third-quarter 2025 adjusted earnings per share (EPS) of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%. You may see the entire listing of right now’s Zacks #1 Rank shares right here.
ISRG has an estimated long-term earnings progress charge of 15.7% in contrast with the trade’s 11.9% progress. The corporate’s earnings outpaced estimates in every of the trailing 4 quarters, the common shock being 16.34%.
Medpace, at the moment carrying a Zacks Rank #2, reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%.
MEDP has an estimated earnings progress charge of 17.1% for 2025 in contrast with the trade’s 16.6% progress. The corporate’s earnings beat estimates in every of the trailing 4 quarters, the common shock being 14.28%.
Boston Scientific, at the moment carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings progress charge of 16.4% in contrast with the trade’s 13.5% progress. The corporate’s earnings beat estimates in every of the trailing 4 quarters, the common shock being 7.36%.
Zacks Naming High 10 Shares for 2026
Wish to be tipped off early to our 10 high picks for the whole thing of 2026? Historical past suggests their efficiency might be sensational.
From 2012 (when our Director of Analysis Sheraz Mian assumed accountability for the portfolio) by way of November, 2025, the Zacks High 10 Shares gained +2,530.8%, greater than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing by way of 4,400 corporations to handpick the perfect 10 tickers to purchase and maintain in 2026. Don’t miss your probability to get in on these shares once they’re launched on January 5.
Be First to New High 10 Shares >>
Boston Scientific Company (BSX) : Free Inventory Evaluation Report
Intuitive Surgical, Inc. (ISRG) : Free Inventory Evaluation Report
Medpace Holdings, Inc. (MEDP) : Free Inventory Evaluation Report
Co-Diagnostics, Inc. (CODX) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
